222 related articles for article (PubMed ID: 36401042)
1. Preparation of NanoMEDIC Extracellular Vesicles to Deliver CRISPR-Cas9 Ribonucleoproteins for Genomic Exon Skipping.
Watanabe K; Gee P; Hotta A
Methods Mol Biol; 2023; 2587():427-453. PubMed ID: 36401042
[TBL] [Abstract][Full Text] [Related]
2. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping.
Gee P; Lung MSY; Okuzaki Y; Sasakawa N; Iguchi T; Makita Y; Hozumi H; Miura Y; Yang LF; Iwasaki M; Wang XH; Waller MA; Shirai N; Abe YO; Fujita Y; Watanabe K; Kagita A; Iwabuchi KA; Yasuda M; Xu H; Noda T; Komano J; Sakurai H; Inukai N; Hotta A
Nat Commun; 2020 Mar; 11(1):1334. PubMed ID: 32170079
[TBL] [Abstract][Full Text] [Related]
3. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
[TBL] [Abstract][Full Text] [Related]
4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
5. Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades").
Mangeot PE; Guiguettaz L; Sohier TJM; Ricci EP
J Vis Exp; 2021 Mar; (169):. PubMed ID: 33871447
[TBL] [Abstract][Full Text] [Related]
6. A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation.
Zhang Y; Nishiyama T; Li H; Huang J; Atmanli A; Sanchez-Ortiz E; Wang Z; Mireault AA; Mammen PPA; Bassel-Duby R; Olson EN
Mol Ther Methods Clin Dev; 2021 Sep; 22():122-132. PubMed ID: 34485599
[TBL] [Abstract][Full Text] [Related]
7. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
8. Construction of an Inducible CRISPR/Cas9 System for CXCR4 Gene and Demonstration of its Effects on MKN-45 Cells.
Peng Y; Yang T; Tang X; Chen F; Wang S
Cell Biochem Biophys; 2020 Mar; 78(1):23-30. PubMed ID: 31875277
[TBL] [Abstract][Full Text] [Related]
9. Divergent susceptibilities to AAV-SaCas9-gRNA vector-mediated genome-editing in a single-cell-derived cell population.
Morsy SG; Tonne JM; Zhu Y; Lu B; Budzik K; Krempski JW; Ali SA; El-Feky MA; Ikeda Y
BMC Res Notes; 2017 Dec; 10(1):720. PubMed ID: 29221488
[TBL] [Abstract][Full Text] [Related]
10. Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency.
Fry LE; Peddle CF; Stevanovic M; Barnard AR; McClements ME; MacLaren RE
CRISPR J; 2020 Aug; 3(4):276-283. PubMed ID: 32833533
[TBL] [Abstract][Full Text] [Related]
11. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice.
Kenjo E; Hozumi H; Makita Y; Iwabuchi KA; Fujimoto N; Matsumoto S; Kimura M; Amano Y; Ifuku M; Naoe Y; Inukai N; Hotta A
Nat Commun; 2021 Dec; 12(1):7101. PubMed ID: 34880218
[TBL] [Abstract][Full Text] [Related]
12. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
13. Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing.
Dubey S; Chen Z; Jiang YJ; Talis A; Molotkov A; Ali A; Mintz A; Momen-Heravi F
Theranostics; 2024; 14(7):2777-2793. PubMed ID: 38773978
[TBL] [Abstract][Full Text] [Related]
14. Encapsulating Cas9 into extracellular vesicles by protein myristoylation.
Whitley JA; Kim S; Lou L; Ye C; Alsaidan OA; Sulejmani E; Cai J; Desrochers EG; Beharry Z; Rickman CB; Klingeborn M; Liu Y; Xie ZR; Cai H
J Extracell Vesicles; 2022 Apr; 11(4):e12196. PubMed ID: 35384352
[TBL] [Abstract][Full Text] [Related]
15. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
Wilbie D; Walther J; Mastrobattista E
Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
[TBL] [Abstract][Full Text] [Related]
16. Efficient Genome Editing Achieved via Plug-and-Play Adenovirus Piggyback Transport of Cas9/gRNA Complex on Viral Capsid Surface.
Lu ZH; Li J; Dmitriev IP; Kashentseva EA; Curiel DT
ACS Nano; 2022 Jul; 16(7):10443-10455. PubMed ID: 35749339
[TBL] [Abstract][Full Text] [Related]
17. Points of View on the Tools for Genome/Gene Editing.
Chuang CK; Lin WM
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576035
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
Zhang Y; Bassel-Duby R; Olson EN
Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
[TBL] [Abstract][Full Text] [Related]
19. Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene.
Majeau N; Fortin-Archambault A; Gérard C; Rousseau J; Yaméogo P; Tremblay JP
Mol Ther; 2022 Jul; 30(7):2429-2442. PubMed ID: 35619556
[TBL] [Abstract][Full Text] [Related]
20. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration.
Zeng W; Zheng L; Li Y; Yang J; Mao T; Zhang J; Liu Y; Ning J; Zhang T; Huang H; Chen X; Lu F
Emerg Microbes Infect; 2024 Dec; 13(1):2284286. PubMed ID: 37982370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
